



Reduced CD27⁻IgD⁻ B Cells in Blood and Raised CD27⁻IgD⁻ B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease

Chathyan Pararasa^{1†}, Na Zhang^{1,2†}, Thomas J. Tull^{1†}, Ming H. A. Chong³,
Jacqueline H. Y. Siu⁴, William Guesdon¹, Konstantia Maria Chavele¹,
Jeremy D. Sanderson⁵, Louise Langmead⁶, Klaartje Kok⁶, Jo Spencer^{1*†} and
Anna Vossenkamper^{3†}

OPEN ACCESS

Edited by:

Marjorie K. De La Fuente,
Clinica Las Condes, Chile

Reviewed by:

Calogero Caruso,
University of Palermo, Italy
Capucine Picard,
Necker-Enfants Malades Hospital,
France

*Correspondence:

Jo Spencer
jo.spencer@kcl.ac.uk

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Mucosal Immunity,
a section of the journal
Frontiers in Immunology

Received: 26 September 2018

Accepted: 12 February 2019

Published: 05 March 2019

Citation:

Pararasa C, Zhang N, Tull TJ,
Chong MHA, Siu JHY, Guesdon W,
Chavele KM, Sanderson JD,
Langmead L, Kok K, Spencer J and
Vossenkamper A (2019) Reduced
CD27⁻IgD⁻ B Cells in Blood and
Raised CD27⁻IgD⁻ B Cells in
Gut-Associated Lymphoid Tissue in
Inflammatory Bowel Disease.
Front. Immunol. 10:361.
doi: 10.3389/fimmu.2019.00361

¹ Peter Gorer Department of Immunobiology, King's College London, Guy's Hospital, London, United Kingdom, ² Obstetrics and Gynecology Hospital, Institutes of Biomedical Sciences (IBS), Fudan University, Shanghai, China, ³ Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom, ⁴ Department of Surgery, Addenbrookes Hospital, University of Cambridge, Cambridge, United Kingdom, ⁵ Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁶ Department of Gastroenterology, Royal London Hospital, Barts Health, London, United Kingdom

The intestinal mucosa in inflammatory bowel disease (IBD) contains increased frequencies of lymphocytes and a disproportionate increase in plasma cells secreting immunoglobulin (Ig)G relative to other isotypes compared to healthy controls. Despite consistent evidence of B lineage cells in the mucosa in IBD, little is known of B cell recruitment to the gut in IBD. Here we analyzed B cells in blood of patients with Crohn's disease (CD) and ulcerative colitis (UC) with a range of disease activities. We analyzed the frequencies of known B cell subsets in blood and observed a consistent reduction in the proportion of CD27⁻IgD⁻ B cells expressing all Ig isotypes in the blood in IBD (independent of severity of disease and treatment) compared to healthy controls. Successful treatment of patients with biologic therapies did not change the profile of B cell subsets in blood. By mass cytometry we demonstrated that CD27⁻IgD⁻ B cells were proportionately enriched in the gut-associated lymphoid tissue (GALT) in IBD. Since production of TNF α is a feature of IBD relevant to therapies, we sought to determine whether B cells in GALT or the CD27⁻IgD⁻ subset in particular could contribute to pathology by secretion of TNF α or IL-10. We found that donor matched GALT and blood B cells are capable of producing TNF α as well as IL-10, but we saw no evidence that CD27⁻IgD⁻ B cells from blood expressed more TNF α compared to other subsets. The reduced proportion of CD27⁻IgD⁻ B cells in blood and the increased proportion in the gut implies that CD27⁻IgD⁻ B cells are recruited from the blood to the gut in IBD. CD27⁻IgD⁻ B cells have been implicated in immune responses to intestinal bacteria and recruitment to GALT, and may contribute to the intestinal inflammatory milieu in IBD.

Keywords: memory B cells, inflammatory bowel disease, GALT, mass cytometry, biologics, ustekinumab, infliximab

INTRODUCTION

Inflammatory bowel disease (IBD) encompasses two clinical entities: Crohn's disease (CD) and ulcerative colitis (UC). Both are chronic debilitating diseases characterized by relapsing intestinal inflammation. While the exact etiology of both diseases is still not clearly understood, current literature suggests that an aberrant immune response to the intestinal flora contributes to pathology in genetically susceptible individuals (1–3). The evidence for this is however stronger for CD than for UC (4), which can be associated with autoimmune conditions like primary sclerosing cholangitis (PSC) in a small subgroup of patients (5). CD is a condition hallmarked by granulomatous transmural inflammation that can affect the entire gastrointestinal tract and is frequently complicated by fistulae and strictures. In contrast, UC is predominantly a disease affecting the rectum and distal colon, where it manifests as ulceration limited to the mucosal layer. However, rectum-sparing forms of UC are known to exist and in rare cases the pathology can extend into the terminal ileum (6, 7). Whilst big strides have been made in developing biologic therapies for both diseases, a significant proportion of patients with CD and UC remain treatment refractory, highlighting the unmet need for a better understanding of the mechanisms contributing to the pathogenesis of both diseases (8, 9).

Most immunological research in CD and UC has focused on T lymphocytes and macrophages that infiltrate the mucosa in active disease (10–12). Th1 and Th17 cells have been implicated especially in the pathogenesis of CD, whilst their role in UC is still not fully understood (13, 14). UC is also characterized by the infiltration of neutrophils into the inflamed mucosa, where they are proposed to have a pathogenic role by the maintenance of inflammation (15). However, in both CD and UC, a significant increase in the number of plasma cells in the lamina propria has been observed and linked to disease pathogenesis (16–18).

The gut-associated lymphoid tissue (GALT) comprises the appendix, Peyer's patches in the ileum and isolated lymphoid follicles in the small and large intestine. GALT is the inductive site for the generation of protective immune responses against enteric pathogens as well as the tolerogenic response to commensal species (19). Interestingly, the appendectomy of the (inflamed) appendix at a young age has been correlated with a reduced risk of developing UC later in life (20). The underlying mechanism of this protective effect is unknown; however, it strongly suggests that an aberrant immune response in the appendix can predispose to UC. In addition, several reports have described appendiceal inflammation in patients with UC affecting only the distal parts of the colon (21, 22). Based on these studies that suggest that plasma cells, B cells and GALT could be implicated in the development of IBD, we sought to study the B cell populations in blood and GALT of CD and UC patients. In addition, we aimed to study the gut-homing capacity of the different populations in blood by investigating the expression of

the $\beta 7$ subunit of $\alpha 4\beta 7$ integrin in active disease vs. remission. We further looked at how the three main biologic treatments for IBD, the anti-TNF treatment infliximab, the anti- $\alpha 4\beta 7$ integrin treatment vedolizumab, and the anti-IL12/IL23 p40 antibody ustekinumab affect peripheral B cell subsets in IBD. While several B cell aberrations in blood and GALT in IBD were observed, we focus this report on the poorly understood CD27⁺ IgD⁺ population that are likely to be unconventional memory B cells (23–27), that we found to be consistently depleted in CD and UC blood, but enriched in GALT.

MATERIALS AND METHODS

Sample Collection

All recruited IBD patients had a confirmed diagnosis of either CD or UC and took part with informed written consent. The study was approved by the local ethics committee (REC 10/H0704 and REC 15/LO/2127). Blood samples were obtained from patients who attended the biologics infusion clinic or the outpatient IBD clinic for a routine review. Controls for the study of blood cells were healthy donors who were age and gender matched to the patients in each group. Endoscopic samples were taken from IBD patients undergoing routine colonoscopies to assess disease activity, and from patients undergoing polypectomy who had no signs of intestinal inflammation, serving as controls. GALT samples were obtained by targeted biopsies of ileal Peyer's patches and the appendiceal orifice. Mononuclear cells from biopsies were isolated using a collagenase digest as previously described (28). Blood samples were collected in sodium heparin tubes and peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (GE Healthcare, Amersham, UK) density gradient centrifugation as previously described (28). PBMCs were cryopreserved using fetal bovine serum (FBS)/10% dimethyl sulfoxide (DMSO; both Sigma Aldrich, Gillingham, UK) and stored in the vapor phase of liquid nitrogen until use. An overview of recruited patients is provided in **Supplemental Tables 1, 2**. For cell sorting experiments blood cones from healthy donors were purchased from NHS Blood and Transplant (Tooting, UK).

Patient Stratification

We included 10 patients receiving infliximab (8 CD and 2 UC; 55% female, median age 41); six patients receiving vedolizumab (1 CD and 5 UC, 50% female, median age 32), and 14 CD patients receiving ustekinumab (50% female, median age 32). Patients received:

- Intravenous (IV) ustekinumab (Stelara[®]) 6 mg/kg (induction) and 90 mg subcutaneously every 8 weeks from week 8.
- IV infliximab (Remsima[®]) 5 mg/kg at week 0, 2, and 6 thereafter every 8 weeks.
- IV vedolizumab (Entyvio[®]) 300 mg at week 0, 2, and 6 and thereafter every 8 weeks.

Blood samples were prospectively collected pre-treatment (week 0), at 6 weeks (infliximab and vedolizumab) or 8 weeks (ustekinumab). Clinical response/remission was assessed at week 14 (infliximab and vedolizumab) or week 16 (ustekinumab).

Abbreviations: IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; HC, healthy control; CRP, C-reactive peptide; GALT, gut-associated lymphoid tissue.

Clinical remission was defined as Harvey-Bradshaw index (HBI) <5 or partial Mayo score 0–1 at week 14/16 (29, 30). Clinical response was defined as HBI reduction ≥ 3 or partial Mayo score reduction ≥ 2 for patients with inactive disease at baseline, or $>30\%$ reduction if disease activity index was abnormal (HBI ≥ 5 , partial Mayo ≥ 2) at week 0. Biological response was defined as a 50% reduction in CRP, if baseline CRP >5 mg/l. Biological remission was defined as CRP <5 mg/l (31).

Multi-Parameter Flow Cytometry

Frozen PBMCs from healthy volunteers and IBD patients were thawed, washed and rested for 45 min in RPMI-1640 containing 10% FBS, 100 U/ml penicillin/100 μ g/ml streptomycin (all Gibco/Thermo Fisher Scientific, Waltham, MA, USA), with DNase I (0.1 mg/ml; from Roche, Welwyn Garden City, UK). Cells were resuspended in PBS prior to live dead staining with Zombie Aqua (Biolegend, San Diego, CA, USA). Cells were then stained with fluorochrome conjugated monoclonal antibodies to CD19, CD27, CD10, IgA, IgD, IgM, and integrin $\beta 7$ (Supplemental Table 3). Cells were analyzed using a BD Biosciences LSR Fortessa flow cytometer (Wokingham, UK) before determination of B cell populations using the gating strategy shown in Figure 1. Further detail and explanation are provided in Supplemental Figure 1 and Supplemental Table 4. IgG was not used in the flow cytometry panel, but preliminary experiments demonstrated that cells lacking IgM, IgA (and IgD for the CD27⁻ subset) could be reasonably classified as IgG⁺, so this method was used to reduce antibodies in the panel. One of five test experiments is illustrated in Supplemental Figure 2. Although theoretically IgE expressing B cells could have been included, these are known to be very small in number and are difficult to detect due to the possibility of IgE binding to Fc receptors.

Cell Sorting

Frozen blood cone derived PBMCs were thawed, washed and rested in RPMI-1640 containing 10% FBS, 100 U/ml penicillin/100 μ g/ml streptomycin, and DNase I (0.1 mg/ml) for 45 min. Cells were stained with DAPI, anti-CD19, CD27, and IgD prior to sorting using a BD Biosciences FACS Aria II Cell Sorter. B cells were sorted initially by CD19 expression, with four populations isolated based on CD27 and IgD expression: CD27⁺IgD⁻, CD27⁻IgD⁻, CD27⁺IgD⁺, and CD27⁻IgD⁺ (Supplemental Figure 3A).

Analysis of Intracellular Cytokines

Unsorted cell suspensions or B cell populations sorted by FACS were suspended in RPMI-1640 containing 10% FBS, 100 U/ml penicillin/100 μ g/ml streptomycin and seeded into 96 well plates prior to stimulation with 250 ng/ml ionomycin, 50 ng/ml PMA (both Sigma) and GolgiStop (1:1,000; BD Biosciences) for 4 h. Cells were washed and resuspended with PBS prior to live dead staining with Zombie Aqua. Subsequently, cells were washed and fixed with 2% paraformaldehyde, prior to treatment with permeabilization buffer (both eBioscience/Thermo Fisher Scientific). Cells were stained with anti-TNF α (Mab11,

BioLegend, 1:50) and anti-IL10 (JES3-19F1, BioLegend, 1:20) and data acquired using a FACS Canto II instrument (BD Biosciences). See Supplemental Figure 4 for gating strategies for analysis of cytokine production by whole CD19⁺ populations from GALT and blood and Supplemental Figure 3 for sorting CD27⁺IgD⁻, CD27⁻IgD⁻, CD27⁺IgD⁺, and CD27⁻IgD⁺ populations and for analysis of cytokine production by cultured sorted cells.

Mass Cytometry

Cells isolated from healthy control mucosal biopsy samples ($n = 6$) and IBD (UC: $n = 6$ and CD: $n = 1$) were washed and rested in RPMI-1640 10% FBS, 100 U/ml penicillin/100 μ g/ml streptomycin and DNase I (0.1 mg/ml) for 30 min. Cell counts were obtained using trypan blue (Sigma) on a Countess II FL cell counter (Thermo Fisher Scientific). From each sample two million live cells were stained with Cell-ID Intercalator-103 Rh (1:500; Fluidigm, San Francisco, CA, USA) for DNA for 15 min. After washing cells were stained with metal-conjugated antibodies (Supplemental Table 5) for 30 min, then washed and fixed in 2% paraformaldehyde overnight at 4°C. Cells were pelleted and frozen in FBS/10% DMSO at -80°C for no longer than 14 days. On the day of the mass cytometry run, cells were thawed and washed prior to incubation with 0.3% saponin with Cell-ID Intercalator-Ir for 20 min to permeabilize and live/dead stain, respectively (32). Cells were then washed with PBS followed by two water washes before being run into a Fluidigm Helios mass cytometry instrument.


Data Analysis

Flow cytometry data was analyzed in FlowJo software (FlowJo LCC, Ashland, Oregon, USA) to identify nine B cell populations, as described in Figure 1, Supplemental Figures 1, 2, and Supplemental Table 4. The designation of cells that do not express IgM or IgA (or IgD for CD27⁻ cells) as IgG⁺ was based on preliminary experiments Supplemental Figure 2.

Mass cytometry data was analyzed using cloud-based cytometry platform, Cytobank (Santa Clara, CA USA <https://mrc.cytobank.org>). Bead-based normalization of the individual mass cytometry data was performed with the Normalizer v0.3 software from Garry P. Nolan Laboratory (downloaded from <https://github.com/nolanlab/bead-normalization/releases/tag/v0.3>). Supplemental Figure 5A shows pre and post-normalization plots. Normalized files were gated as shown in Supplemental Figures 5B,C after uploading onto Cytobank to remove doublets by gating on DNA and removing cells with implausible marker combinations. Data was generated by further subset gating in Cytobank.

Statistical Analysis

Statistical testing was performed using GraphPad software (La Jolla, CA, USA). Individual groups were compared using Mann-Whitney U non-parametric test. Multiple groups were compared using Kruskal-Wallis ANOVA. A $p < 0.05$ was considered significant. Identifiers of statistical values derived from Kruskal-Wallis ANOVA are identified with red lines and asterisks in the



figures. Identifiers of statistical values derived using the Mann-Whitney *U* test are identified with black lines and asterisks in the figures.

RESULTS

Altered B Cell Subset Frequencies in Peripheral Blood of IBD Patients

In order to assess relative frequencies of the main B cell subsets in peripheral blood of CD and UC patients, we subjected the PBMCs of patients with various disease activities and treatments (see **Supplemental Table 1**) to six color flow cytometry. B cell subsets were gated as described in **Figure 1**, **Supplemental Figure 1** and **Supplemental Table 4**. In UC blood we observed a moderate reduction of transitional B cells (CD27⁻IgM⁺IgD⁺CD10⁺) and an increase in marginal zone B cells (CD27⁺IgM⁺IgD⁺) compared to controls (**Figure 2**). The frequencies of naive, CD27⁺ IgA⁺, and CD27⁺IgM⁺ subsets did not differ between IBD and controls (**Figure 2**). In UC blood, the frequency of CD27⁺IgG⁺ was increased compared to both HC and CD (**Figure 2**). Interestingly, the most striking difference compared to controls was the overall reduction of CD27⁻IgD⁻ populations expressing IgM, IgA or IgG in the blood of both UC and CD patients (**Figure 2**).

Increased Frequencies of CD27⁻IgD⁻ B Cells in IBD GALT

Since the proportion of CD27⁻IgD⁻ B cells of total CD19 B cells was reduced in blood of patients with IBD, we asked whether this is also a feature of B cells in GALT of patients with IBD. To answer this specific question, we interrogated a large dataset

available in our lab that had been generated by mass cytometric analysis of cells isolated from GALT of healthy individuals and patients with IBD. Following initial normalization and quality control we analyzed the data by manually gating the .fcs files in Cytobank (**Supplemental Figure 5**, **Supplemental Table 4** and **Figure 3**). We initially gated on CD19⁺ cells and then excluded CD10⁺ cells since these would include germinal center cells that are not comparable with blood. We then analyzed the frequencies of CD27⁺IgD⁻, CD27⁻IgD⁻, CD27⁺IgD⁺, and CD27⁻IgD⁺ B cells and observed an increase in the proportion of CD27⁻IgD⁻ cells and a reduction in CD27⁻IgD⁺ cells in GALT in IBD. This demonstrated that the CD27⁻IgD⁻ B cell subset is not globally depleted in patients with IBD.

Expression of Gut-Homing Marker Beta7 Integrin on CD27⁻IgD⁻ B Cells

The enrichment of CD27⁻IgD⁻ cells in GALT in IBD, and the reduction of all subsets of this population expressing IgM, IgA, and IgG in blood in IBD, implies that CD27⁻IgD⁻ cells may be recruited from the blood to the gut in IBD. Therefore, we went on to investigate the gut-homing capacity of those cells in blood of UC and CD patients by analyzing the expression of $\alpha 4\beta 7$ integrin (by staining the $\beta 7$ sub-unit). In addition, we were interested in determining whether this might differ in active disease compared to remission state. For the analysis samples were retrospectively stratified into raised C-reactive peptide (CRP >5 mg/l, indicating active inflammation) and normal CRP (CRP <5 mg/l). Samples were also stratified by a global clinical assessment of the patients being having active disease compared to being in remission.





FIGURE 2 | Analysis of B cell subsets in healthy controls and IBD patients. Peripheral blood mononuclear cells from IBD and HC patients were stained using fluorescent antibodies and gated according to the strategy in **Figure 1** and **Supplemental Table 4**. Data is presented as percentage of total CD19 positive cells from each individual HC ($n = 22$), UC patient ($n = 17$), and CD patient ($n = 35$). Patients with UC in are represented with blue symbols. Symbols that are lighter blue with black borders are patients in remission. Patients with CD in are represented with green symbols. Symbols that are lighter green with black borders are patients in remission. Differences between groups were analyzed by Mann-Whitney U test where $p < 0.05 = *$, $p < 0.01 = **$, $p < 0.001 = ***$, and $p < 0.0001 = ****$.

The frequency of $CD27^{-}IgA^{+}$ cells was slightly raised in UC patients with $CRP > 5$ compared to $CRP < 5$ and the expression of $\beta 7$ integrin increased when CRP was elevated. A similar trend was observed for the CD samples but did not reach significance (**Figures 4A,B**). In UC with $CRP > 5$, the frequencies of $CD27^{-}IgG^{+}$ cells and $CD27^{-}IgM^{+}IgD^{-}$ cells showed a non-significant trend toward being raised with increased $\beta 7$ expression. No differences were seen for those two subsets and $\beta 7$ in CD with a $CRP > 5$ in terms of % positive cells (**Figure 4B**), however MFI of $\beta 7$ integrin expression was lower in $CD27^{-}IgM^{+}IgD^{-}$ cells in patients with CD when $CRP > 5$ compared to < 5 (**Supplemental Figure 6**). When patients were stratified clinically into either active disease or in remission, we still observed a bias toward reduced proportion of $CD27^{-}IgD^{-}$ cells. The reduction of $CD27^{-}IgD^{-}$ was significantly reduced in blood from CD patients compared to HC independently of disease activity (**Figure 4C**). For the UC samples we observed a non-significant trend of such a reduction. The expression of $\beta 7$ integrin on $CD27^{-}$ cells in CD blood as either % positive cells or MFI tended to be raised but values did not reach statistical significance (**Figure 4D** and **Supplemental Figure 6**).

Treatment With Biologics has Little Impact on Blood $CD27^{-}IgD^{-}$ Cells in IBD

Treatment escalation in advanced CD and UC cases involves the use of biologic treatments. The most frequently used are the anti-TNF antibody infliximab and the anti- $\alpha 4\beta 7$ antibody vedolizumab for UC and CD. The latter disease can also be treated with the anti-p40 antibody ustekinumab. Little is known how those antibodies affect blood B cells populations. While we did not anticipate a direct effect of these drugs on B cells, we wondered whether the induction of remission and hence improved gut barrier function could have an impact. $CD27^{-}IgD^{-}$ cells have been shown to be responsive to bacterial antigens (33). Therefore, we hypothesized that mucosal healing during the course of treatment might affect the proportion of $CD27^{-}IgD^{-}$ B cells in the blood stream of IBD patients. Infliximab treatment (sample obtained at week 6; “post”) did not change the frequencies of $CD27^{-}IgA^{+}$, $CD27^{-}IgG^{+}$, or $CD27^{-}IgM^{+}IgD^{-}$ populations compared to the corresponding sample taken before treatment commenced (**Figure 5A**). The effect of vedolizumab was also assessed at week 6 (“post”) and, interestingly, only the $CD27^{-}IgA^{+}$ population was increased compared to the sample taken before treatment




(“pre”; **Figure 5B**), suggesting that vedolizumab retains this population in the blood by blocking gut homing via $\alpha 4\beta 7$. The CD27⁻IgG⁻, and CD27⁻IgM⁺IgD⁻ populations were lower in IBD blood compared to controls but did not change during treatment (**Figure 5B**). Ustekinumab treatment mildly lowered the frequency of CD27⁻IgA⁺ cells (week 16; post, compared to treatment start; pre. **Figure 5C**) but did not affect the frequencies of CD27⁻IgG⁺, or CD27⁻IgM⁺IgD⁻ cells (**Figure 5C**).

B Cells in GALT Produce TNF α and IL-10

Since our data show that B cell subsets are represented differently in blood and GALT, we wondered whether those B cells might be capable of producing cytokines such as TNF α and IL-10 (34). We analyzed B cells isolated from blood and two GALT sites: the Peyer’s patches in the terminal ileum and colonic follicles in the rectum from the same donors for their production of intracellular TNF α and IL10 (**Supplemental Figure 4**). Compared to the donor-matched PBMCs, the B cells in healthy GALT showed greater tendency to produce TNF α (~25% compared to 10%).

Interestingly, slightly more B cells isolated from colonic follicles produced TNF α than their counterparts isolated from Peyer’s patches. B cells in GALT from CD patients also tended to produce more TNF α than the corresponding PBMCs (**Figure 6A**). In both health and CD, PBMCs and matching GALT B cells were able to produce IL-10 (around 20% of all B cells). There was a non-significant trend for more B cells producing IL-10 in blood compared to GALT (**Figure 6B**).

To determine if CD27⁻IgD⁻ B cells might differ in cytokine production and therefore might differ in their potential to drive inflammation compared to other subsets, FACS sorted CD27⁺IgD⁻, CD27⁻IgD⁻, CD27⁺IgD⁺, and CD27⁻IgD⁺ B cells underwent intracellular staining and flow cytometry for intracytoplasmic TNF α and IL-10 (**Supplemental Figure 3**). CD27⁺IgD⁻, CD27⁻IgD⁻, CD27⁺IgD⁺ populations but fewer CD27⁻IgD⁺ B cells had intracytoplasmic TNF α (**Figure 6C**). In contrast, neither CD27⁺IgD⁻, CD27⁻IgD⁻ nor CD27⁺IgD⁺ cells produced IL10 following stimulation, while between 5 and 20% CD27⁻IgD⁺ cells produced IL-10 (**Figure 6D**).



DISCUSSION

In this study we aimed to gain insights into the peripheral B cell subsets in IBD and how those subsets might differ between active disease and the state of remission. We observed a consistent proportionate reduction of CD27⁻ IgD⁻ B cells expressing IgM, IgA, and IgG in the blood in IBD and an enrichment of the CD27⁻ IgD⁻ subset in GALT in IBD, consistent with recruitment of CD27⁻ IgD⁻ B cells from the blood to the gut in IBD. Depletion of CD27⁻ IgD⁻ B cells from the blood is seen in patients with both CD and UC even when patients are in remission and when disease activity is low. Although, differences

in transitional B cells, marginal zone B cells and CD27⁺ IgG⁺ B cells were observed, mainly between UC and controls, this could be in compensation for the relative fall in the CD27⁻ IgD⁻ subset, as populations were quantified with CD19⁺ cells remaining at 100% and total B cell counts were not determined. We propose that the major feature of the data is the depletion of CD27⁻ IgD⁻ subsets of B cells because this was observed consistently across all isotypes and despite the different gating strategies required for their identification from the blood of patients with UC and CD.

The white blood count in IBD can be altered during a disease flare or lowered by treatments like azathioprine and methotrexate (35). However, we also observed our findings in





FIGURE 5 | CD27⁻IgD⁻ B cells subsets in blood of CD and UC patients treated with biologics. Patients were treated with either **(A)** infliximab ($n = 10$, HC $n = 9$), **(B)** vedolizumab ($n = 6$, HC $n = 5$), or **(C)** ustekinumab ($n = 14$, HC $n = 12$) with a baseline (pre) and a post-treatment (6 weeks for infliximab and vedolizumab, and 8 weeks for ustekinumab) sample obtained. Subsets of CD27⁻IgD⁻ cells were compared to age and gender matched healthy controls (Dark blue squares: UC patients responsive to treatment; Dark blue asterisks: UC patients non-responsive to treatment; Green triangles: CD patients responsive to treatment; Green asterisks: CD patients non-responsive to treatment). Data was analyzed by Mann-Whitney U tests where $p < 0.05 = *$, $p < 0.01 = **$, $p < 0.001 = ***$ and $p < 0.0001 = ****$.

patients with only mild disease or remission, and most patients were not on treatments that cause lymphopenia, suggesting the observed reduction of CD27⁻IgD⁻ subsets is not directly linked to treatment or a flare.

As we were interested in whether peripheral B cell subsets are affected by disease activity in CD and UC, we stratified patients based on their CRP values (CRP > 5 mg/l as a marker of ongoing inflammation) and based on clinical scoring by a clinical gastroenterologist. Interestingly, we observed higher frequencies of CD27⁻IgA⁺ cells and an increase in $\beta 7$ integrin on those cells in blood of UC patients with raised CRP levels. This was not significant for UC patients stratified clinically (**Figure 4**). Treatment with the antibody vedolizumab significantly raised the frequency of this subset during treatment (measured at 6 weeks; **Figure 5B**), suggesting that blood CD27⁻IgA⁺ B cells are retained in blood by vedolizumab which hinders gut homing by blocking $\alpha 4\beta 7$. Interestingly, treatment with infliximab and ustekinumab did not have much effect on blood frequencies of CD27⁻IgD⁻ B cells. We only noticed a mild reduction in CD27⁻

IgA⁺ cells at 8 weeks of ustekinumab treatment (**Figure 5C**). Whether this finding is of therapeutic relevance remains to be determined.

CD27⁻IgD⁻ B cells comprise ~5% of blood B cells in healthy individuals and are considered to be part of the memory B cell pool because they have mutations in their Ig heavy chain genes consistent with having transited through a germinal center (23–27). However, the role of these cells is not understood. They have been associated with aging and inflammatory diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Alzheimer's disease, in which increased frequencies are present in the blood (36–39). Whilst the cause of the increase is not known, this double negative subset has been described as responsive to anti-inflammatory treatments; anti-TNF therapy in RA reduced the cell frequency (40), and conventional treatment in SLE increased it (36). It is therefore very interesting that the change in frequency of CD27⁻IgD⁻ B cells in IBD is in the opposite direction to that observed in aging and other disease settings, and that we do not observe changes in response



to biologic therapies. As is often the case with studies of inflammatory diseases, we cannot rule out the possibility that medication given at some time may have induced the changes we see. However, other inflammatory diseases may share the same therapeutic strategies, suggesting that the reduced frequency of CD27 $^{-}$ IgD $^{-}$ B cells in IBD is a feature of the condition rather than its treatment.

It has been suggested previously that CD27 $^{-}$ memory B cells are associated with intestinal B cell responses (25, 33). They are increased in frequency in healthy GALT compared to other lymphoid tissues (41), CD27 $^{-}$ IgA $^{+}$ memory cells have been shown to have a distinctive repertoire and a bias toward lambda light chain usage. They are polyspecific and able to bind multiple bacterial species in health (33). CD27 $^{-}$ IgA $^{+}$ memory B cells have also been reported to be generated by T cell independent immune responses since they are present in the blood of patients with deficient CD40/CD40L interactions (25). The increased frequency of CD27 $^{-}$ IgD $^{-}$ B cells we observe in GALT in IBD in our study may be due to local proliferation of this subset in response to local challenge rather than selective recruitment from the blood. On the other hand, and in contrast, it has also been suggested that CD27 $^{-}$ memory B cells are part of the normal spectrum of conventional memory B cells since clones of B cells can span the CD27 $^{+}$ and CD27 $^{-}$ subsets

(26). In this case, loss or gain of CD27 from members of a clone may reflect time or tissue context rather than lineage or clone specificity.

Our data linking CD27 $^{-}$ IgD $^{-}$ B cells with intestinal inflammation and their relative depletion from the blood and enhanced frequencies in gut would be consistent with the concept that they are a distinct population with a role in antibacterial immunity. The mucosal barrier is known to be disrupted to varying degrees in IBD so that the local bacterial challenge is likely to be higher (42). UC and CD have markedly different pathogeneses and are impacted by different genetic predispositions and environmental drivers. It is interesting therefore that they share the feature of depletion of CD27 $^{-}$ B cells from the blood. This suggests that recruitment of CD27 $^{-}$ B cells to the gut is more likely a response to an intestinal challenge rather than a feature of the disease process *per se*. This is potentially also the case in quiescent IBD as persistent changes to epithelial barrier function have been described in UC patients who had no mucosal defects (43, 44).

Since our data shows that GALT B cells and blood B cells, including CD27 $^{-}$ IgD $^{-}$ memory cells, are able to produce TNF α , we suggest that increased recruitment of these cells to the gut might contribute to the inflammatory milieu in IBD.

AUTHOR CONTRIBUTIONS

JS and AV designed the study and wrote the manuscript. CP performed flow cytometric analysis and mass cytometry. NZ, TT, and JaS performed experimental design, mass cytometry, data analysis, and data visualization. MC performed sample preparation and flow cytometry. WG and KC analyzed B cell cytokine production. KK, AV, JeS, and LL provided clinical samples and stratified patients by treatment response. All authors contributed to the final manuscript.

FUNDING

This study was funded by Crohn's and Colitis UK, the Medical Research Council of Great Britain (MR/L009382/1, MR/P021964/1, and MR/R000964/1), the Gates Cambridge Trust, The St Thomas' Lupus Trust, KC Wong Education Foundation and the National Institute for Health Research

REFERENCES

- Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature*. (2007) 448:427–34. doi: 10.1038/nature06005
- Murdoch TB, Xu W, Stempak JM, Landers C, Targan SR, Rotter JJ, et al. Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease. *Inflamm Bowel Dis*. (2012) 18:1743–8. doi: 10.1002/ibd.22884
- de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. *Nat Rev Gastroenterol Hepatol*. (2016) 13:13–27. doi: 10.1038/nrgastro.2015.186
- Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. *J Gastroenterol*. (2011) 46:479–86. doi: 10.1007/s00535-010-0368-4
- Khan N, Trivedi C, Shah Y, Cole E, Lewis J, Yang YX. The natural history of newly diagnosed ulcerative colitis in patients with concomitant primary sclerosing cholangitis. *Inflamm Bowel Dis*. (2018) 24, 2062–7. doi: 10.1093/ibd/izy106
- Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med*. (2009) 361:2066–78. doi: 10.1056/NEJMra0804647
- Horio Y, Uchino M, Bando T, Chohno T, Sasaki H, Hirata A, et al. Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies. *BMC Surg*. (2017) 17:59. doi: 10.1186/s12893-017-0255-5
- Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes. *Med Res Rev*. (2008) 28:201–18. doi: 10.1002/med.20103
- Scribano ML. Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence. *World J Gastroenterol*. (2018) 24:2457–67. doi: 10.3748/wjg.v24.i23.2457
- Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. *Gut*. (2008) 57:1682–9. doi: 10.1136/gut.2007.135053
- Caprioli F, Bose F, Rossi RL, Petti L, Viganò C, Ciafardini C, et al. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. *Inflamm Bowel Dis*. (2013) 19:729–39. doi: 10.1097/MIB.0b013e318280292b
- Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. *Immunol Rev*. (2014) 260:102–17. doi: 10.1111/imr.12192
- Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. *Gut*. (2009) 58:1629–36. doi: 10.1136/gut.2009.182170
- (NIHR) Biomedical Research Center based at Guy's and St Thomas' NHS Foundation Trust and King's College London. AV receives funding from GlaxoSmithKline.

ACKNOWLEDGMENTS

We are very grateful to the staff at the endoscopy unit and infusion clinic at the Royal London hospital, as well as all patients who kindly contributed to this study. We would like to thank Dr. Richard Ellis and Dr. Susanne Heck (Biomedical Research Center, Guy's Hospital) for support with mass cytometry. We thank Dr. Gary Warnes (Blizard Institute) for support with FACS.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00361/full#supplementary-material>

26. Wu Y-CB, Kipling D, Dunn-Walters DK. The Relationship between CD27 negative and positive B cell populations in human peripheral blood. *Front Immunol.* (2011) 2:81. doi: 10.3389/fimmu.2011.00081
27. Clavarino G, Delouche N, Vettier C, Laurin D, Pernollet M, Raskovalova T, et al. Novel strategy for phenotypic characterization of human B lymphocytes from precursors to effector cells by flow cytometry. *PLoS ONE.* (2016) 11:e0162209. doi: 10.1371/journal.pone.0162209
28. Vossenkamper A, Hundsrucker C, Page K, van Maurik A, Sanders TJ, Stagg AJ, et al. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease. *Gastroenterology.* (2014) 147:172–83. doi: 10.1053/j.gastro.2014.03.049
29. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. (1980) 1:514.
30. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med.* (1987) 317:1625–9. doi: 10.1056/NEJM198712243172603
31. Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. *Nat Clin Pract Gastroenterol Hepatol.* (2005) 2:580. doi: 10.1038/ncpgasthep0359
32. Sumatoh HR, Teng KW, Cheng Y, Newell EW. Optimization of mass cytometry sample cryopreservation after staining. *Cytometry A.* (2017) 91:48–61. doi: 10.1002/cyto.a.23014
33. Berkowska MA, Schickel JN, Grosserichter-Wagener C, de Ridder D, Ng YS, van Dongen JJ, et al. Circulating human CD27-IgA+ memory B cells recognize bacteria with polyreactive Igs. *J Immunol.* (2015) 195:1417–26. doi: 10.4049/jimmunol.1402708
34. Lighaam LC, Unger PA, Vredevoogd DW, Verhoeven D, Vermeulen E, Turksma AW, et al. *In vitro*-induced human IL-10(+) B cells do not show a subset-defining marker signature and plastically co-express IL-10 with pro-inflammatory Cytokines. *Front Immunol.* (2018) 9:1913. doi: 10.3389/fimmu.2018.01913
35. Meijer B, Wilhelm AJ, Mulder CJJ, Bouma G, van Bodegraven AA, de Boer NKH. Pharmacology of thiopurine therapy in inflammatory bowel disease and complete blood cell count outcomes: a 5-year database study. *Ther Drug Monit.* (2017) 39:399–405. doi: 10.1097/FTD.0000000000000414
36. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieve JA. Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. *Arthritis Res Ther.* (2010) 12:R108. doi: 10.1186/ar3042
37. Bulati M, Buffa S, Martorana A, Candore G, Lio D, Caruso C, et al. Trafficking phenotype and production of granzyme B by double negative B cells (IgG(+)IgD(-)CD27(-)) in the elderly. *Exp Gerontol.* (2014) 54:123–9. doi: 10.1016/j.exger.2013.12.011
38. Bulati M, Buffa S, Martorana A, Gervasi F, Camarda C, Azzarello DM, et al. Double negative (IgG+IgD-CD27-) B cells are increased in a cohort of moderate-severe Alzheimer's disease patients and show a pro-inflammatory trafficking receptor phenotype. *J Alzheimers Dis.* (2015) 44:1241–51. doi: 10.3233/JAD-142412
39. Tony HP, Roll P, Mei HE, Blumner E, Straka A, Gnuetge L, et al. Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab. *Clin Exp Rheumatol.* (2015) 33:887–94.
40. Moura RA, Quaresma C, Vieira AR, Goncalves MJ, Polido-Pereira J, Romao VC, et al. B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. *PLoS ONE.* (2017) 12:e0182927. doi: 10.1371/journal.pone.0182927
41. Zhao Y, Uduman M, Siu JHY, Tull TJ, Sanderson JD, Wu YB, et al. Spatiotemporal segregation of human marginal zone and memory B cell populations in lymphoid tissue. *Nat Commun.* (2007) 9:3857. doi: 10.1038/s41467-018-06089-1
42. McDonnell M, Liang Y, Noronha A, Coukos J, Kasper DL, Farraye FA, et al. Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. *Inflamm Bowel Dis.* (2011) 17:298–307. doi: 10.1002/ibd.21424
43. Vivinus-Nebot M, Frin-Mathy G, Bziouche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. *Gut.* (2014) 63:744–52. doi: 10.1136/gutjnl-2012-304066
44. Dotti I, Mora-Buch R, Ferrer-Picon E, Planell N, Jung P, Masamunt MC, et al. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. *Gut.* (2017) 66:2069–79. doi: 10.1136/gutjnl-2016-312609

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a past co-authorship with one of the authors AV.

Copyright © 2019 Pararasa, Zhang, Tull, Chong, Siu, Guesdon, Chavele, Sanderson, Langmead, Kok, Spencer and Vossenkamper. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.